• Molecular NameMasoprocol
  • SynonymDihydronorguaiaretic acid; Masoprocolum [INN-Latin]; meso-NDGA; meso-Nordihydroguaiaretic acid; NDGA; Nordihydroguaiaretic acid; Nordihydroguairaretic acid
  • Weight302.37
  • Drugbank_IDDB00179
  • ACS_NO500-38-9
  • Show 2D model
  • LogP (experiment)4.018
  • LogP (predicted, AB/LogP v2.0)3.78
  • pkaN/A
  • LogD (pH=7, predicted)3.78
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.39
  • LogSw (predicted, AB/LogsW2.0)0.61
  • Sw (mg/ml) (predicted, ACD/Labs)0.12
  • No.of HBond Donors4
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds5
  • TPSA80.92
  • StatusFDA approved
  • AdministrationTopical
  • PharmacologyAn antineoplastic drug used to treat skin growths caused by sun exposure.
  • Absorption_valueN/A
  • Absorption (description)Less than 1%-2% is absorbed through the skin over a 4-day period following application.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMasoprocol is spontaneously metabolised into reactive ortho-quinone which further conjugated with glutathione in two steps producing mono and diglutathionyl conjugates. Also glucuronide conjugates are occured.
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose or allergic reaction include bluish coloration of skin, dizziness, severe, or feeling faint, wheezing or trouble in breathing.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A